CEO Colin Hill will take part in a panel entitled “Digital Frontiers: Healthcare in 2050″ on Thursday, June 20 at 4:25pm at the Renaissance Zurich Hotel in Zurich, Switzerland. Other panelists include Jeff Arnold, Chairman and CEO of Sharecare and Sir Muir Gray, Director of Better Value Healthcare.…

CEO Colin Hill will present a keynote address at the Financial Times U.S. Healthcare and Life Sciences Conference on Thursday, June 6 at The Metropolitan Club in New York, NY.…

CEO Colin Hill will take part in a panel entitled “Public Health and Big Data Policies” at the Big Data in Biomedicine Conference on Thursday, May 23 at the Li Ka Shing Center for Learning and Knowledge on the Stanford University campus in Palo Alto, CA.…

Executive Vice President and Co-Founder Dr. Iya Khalil will present a talk on GNS Healthcare’s work with Orion Bionetworks at the One Mind Summit on Thursday, May 16 at 8:15am at Johns Hopkins Medical Institutions in Baltimore, MD.…

GNS aims to help MDs know which treatment will work the best for each patient

When Colin Hill’s father was diagnosed with later-stage prostate cancer last summer, he was treated the same as every other patient with the illness.

This standardized approach bothered Hill, who believes medicine should approach each patient’s illness as unique, with medication tailored to the person’s history and biology.

“You show up to the hospital, and it’s like Groundhog Day,” Hill said, with patients being cared …

Harvard researchers have licensed GNS Healthcare’s REF (Reverse Engineering and Forward Simulation) Big Data analytics platform to build computational models of the mechanisms involved in cell differentiation in hopes of building better treatments.

Beyond learning how cells respond to the different signals they receive, researchers plan to explore how they react to various drugs. They’re expected to generate massive amounts of data using whole genome sequencing, RNA sequencing and high-throughput protein measurements collected over time, according to an announcement.…

Comprehend Systems and GNS Healthcare made progress with very different software tools for drug researchers. Yet both companies have lived up to FierceBiotech IT’s choice to include them in an October 2011 report on tech companies to watch in the biotech arena.

Cambridge, MA-based GNS and Harvard Medical School inked a 5-year deal to give Harvard researchers access to the company’s Big Data analytics technology to study signaling and transcriptional events in cells. The company guarded financial details of the …

GNS Healthcare, Inc. announced today that Harvard Medical School has licensed its REFS™ (Reverse Engineering and Forward Simulation) Big Data analytics platform. Under the five-year license, Harvard researchers will use REFS™ to characterize and understand signaling and transcriptional events in biological systems. Financial terms of the agreement were not disclosed.

“Reverse engineering is a key challenge for systems biology,” said Marc Kirschner, Professor and Chair of the Department of Systems Biology at Harvard Medical School. “Achieving a synergy between the design of experiments and reverse engineering methods will be defining for how we understand biological mechanism in the next century.”

Chief Strategy Officer Carol McCall will give the keynote presentation, “‘Big Data’: Implications for Medical Publications,” at the 9th Annual Meeting of the International Society for Medical Publication Professionals on Tuesday, April 30 at 8:05am at the Hyatt Regency in Baltimore, MD. …

CEO Colin Hill will moderate a panel entitled Big Problems Need Big Solutions- Fixing the Health Care System Using Big Data on Monday, April 22 from 3:45-5:00pm at McCormick Place in Chicago, IL. Panelists include Andrea Marks of Blue Health Intelligence, Brian Sweet of AstraZeneca, and Barbara Tardiff of Pfizer.…